IMM 7.41% 29.0¢ immutep limited

us medicare, page-5

  1. 978 Posts.
    an extract from the DNDN website about the Medicare situation with Provenge. You will see that:

    "Medicare beneficiaries are still able to access PROVENGE and private payers can also still cover PROVENGE.

    cheers
    Birdseye

    here is the extract:

    Dendreon Statement on Centers for Medicare and Medicaid Services- CMS
    SEATTLE, June 30, 2010

    In the announcement, ---CMS is requesting public comments on the effects of PROVENGE on health outcomes in patients with prostate cancer.

    It is NOT a change in Medicare coverage policy.

    ---not impact existing coverage decisions, nor do they restrict local Medicare contractors from covering PROVENGE.
    Therefore, Medicare beneficiaries are still able to access PROVENGE and private payers can also still cover PROVENGE.

    Dendreon welcomes the opportunity to continue our discussions with CMS about how PROVENGE will be provided to Medicare beneficiaries, particularly given the survival benefit and safety profile of PROVENGE. 'We plan on continuing to work closely with CMS during this process to ensure patients with advanced prostate cancer have broad access to PROVENGE.'

    Source:http://investor.dendreon.com/phoenix.zhtml?c=120739&p=irol-newsArticle&ID=1443313&highlight=
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
29.0¢
Change
0.020(7.41%)
Mkt cap ! $421.8M
Open High Low Value Volume
27.5¢ 29.5¢ 27.0¢ $1.138M 3.985M

Buyers (Bids)

No. Vol. Price($)
2 63444 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.5¢ 65000 2
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.